Highlights IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

Market Closed - Nasdaq Stockholm Other stock markets 16:29:47 14/05/2024 BST			5-day change	1st Jan Change
16.2 ^SEK	+3.85%		+58.82%	+116.00%

05-08	Transcript : IRLAB Therapeutics AB, Q1 2024 Earnings Call, May 08, 2024
05-07	IRLAB Therapeutics AB and McQuade Center for Strategic Research and Development, LLC Enter into Development Collaboration for IRL757 as Novel Treatment for Apathy	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IRLAB Therapeutics AB and McQuade Center for Strategic Research and Development, LLC Enter into Development Collaboration for IRL757 as Novel Treatment for Apathy	05-07	CI
IRLAB Has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757	05-06	CI
IRLAB Therapeutics Receives Minutes from End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program for Mesdopetam	03-22	CI
IRLAB Therapeutics AB Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson's Disease Psychosis	03-19	CI
IRLAB Therapeutics AB Completes End-Of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam	02-22	CI
IRLAB Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-07	CI
IRLAB's Pioneering Phase IIb Study Withpirepemat - React-PD - Provides New Insights in Specific Parkinson's Patient Population and Enables a Data Driven Prediction of Study Timelines	02-06	CI
IRLAB Is Granted an End-Of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program	01-03	CI
IRLAB Therapeutics AB's Drug Candidate IRL757 Completes all Preclinical Studies and Development Work Necessary to Start Phase I	12-21	CI
IRLAB Therapeutics AB Receives Grant from the Michael J. Fox Foundation to Support Development of IRL 757 for the Treatment of Apathy	12-21	CI
IRLAB Therapeutics AB Submits Request for an End-Of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program	12-18	CI
Irlab Therapeutics Secures European Patent for Parkinson’s Disease Drug Candidate	12-12	MT
IRLAB Therapeutics AB Receives Additional Patent for Drug Candidate Pirepemat That Expands its Patent Protection	12-12	CI
IRLAB Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	25/10/23	CI
IRLAB Therapeutics AB Signs With Clintrex and ProPharma Group Phase III Regulatory US Consultants to Support Preparation for Mesdopetam?s end-of-Phase 2 Meeting with the US FDA	10/10/23	CI
IRLAB Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	30/08/23	CI
IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam?s Clinical Phase IIb Study in Parkinson?s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen	21/08/23	CI
IRLAB Secures Full Ownership of the Mesdopetam Project and Continues Product Development	21/08/23	CI
IRLAB Therapeutics AB Announces That All Participating Study Sites in the Phase IIb Study of Pirepemat Are Activated and Recruiting Patients	31/05/23	CI
IRLAB Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

Highlights

Filters